Defendant
2 cases as defendant.
Alkem Laboratories Limited, commonly known as Alkem Labs, is an Indian multinational pharmaceutical company headquartered in Mumbai, India. Founded in 1973, it operates as a publicly traded company, listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) under the ticker ALKEM. The company employs over 20,000 individuals and reported revenues around $1.4 billion to $1.6 billion for the financial year ending March 31, 2025.
Alkem Labs specializes in the development, manufacturing, and sale of a diverse range of pharmaceutical and nutraceutical products. Its product portfolio includes branded generics, generic drugs, active pharmaceutical ingredients (APIs), and biosimilars. The company has a significant presence in various therapeutic areas, including anti-infectives, gastroenterology, cardiology, neurology, dermatology, and diabetology. Alkem operates 19 manufacturing facilities in India and two in the United States, alongside multiple R&D centers globally.
In terms of patent litigation, Alkem Labs. Ltd. appears as a defendant in all of its single tracked case, indicating a posture as an operating company defending against intellectual property challenges. The company has no recorded plaintiff cases in the database.
The sole tracked case, Veloxis Pharmaceuticals, Inc. v. Alkem Labs. Ltd., was filed in the District of Delaware on July 3, 2024. This case is an Abbreviated New Drug Application (ANDA) patent infringement action, where Veloxis Pharmaceuticals, Inc. alleged infringement related to Alkem's generic versions of tacrolimus extended-release tablets, corresponding to Veloxis's branded drug ENVARSUS XR®. The case concluded on January 13, 2026.
This appears to be an ANDA case concerning Envarsus XR® (tacrolimus extended-release tablets). The case is currently active.
This is an ongoing ANDA patent infringement case filed by Veloxis Pharmaceuticals, Inc. against Alkem Labs. Ltd. in the District Court, Delaware.